PHARMING GROUP NV - ADR (PHAR) Stock Fundamental Analysis
NASDAQ:PHAR - Nasdaq - US71716E1055 - ADR - Currency: USD
Taking everything into account, PHAR scores 4 out of 10 in our fundamental rating. PHAR was compared to 561 industry peers in the Biotechnology industry. Both the profitability and the financial health of PHAR get a neutral evaluation. Nothing too spectacular is happening here. PHAR is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
PHAR had negative earnings in the past year.
PHAR had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: PHAR reported negative net income in multiple years.
The reported operating cash flow has been mixed in the past 5 years: PHAR reported negative operating cash flow in multiple years.
1.2 Ratios
With an excellent Return On Assets value of -3.50%, PHAR belongs to the best of the industry, outperforming 88.24% of the companies in the same industry.
PHAR has a Return On Equity of -6.59%. This is amongst the best in the industry. PHAR outperforms 89.66% of its industry peers.
PHAR has a Return On Invested Capital of 2.05%. This is amongst the best in the industry. PHAR outperforms 92.34% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.5% | ||
| ROE | -6.59% | ||
| ROIC | 2.05% |
ROA(3y)-0.68%
ROA(5y)2.2%
ROE(3y)-1.17%
ROE(5y)5.07%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
PHAR's Operating Margin of 2.63% is amongst the best of the industry. PHAR outperforms 92.34% of its industry peers.
PHAR has a better Gross Margin (88.98%) than 90.91% of its industry peers.
In the last couple of years the Gross Margin of PHAR has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 2.63% | ||
| PM (TTM) | N/A | ||
| GM | 88.98% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.48%
GM growth 5Y0.17%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), PHAR is destroying value.
The number of shares outstanding for PHAR has been increased compared to 1 year ago.
The number of shares outstanding for PHAR has been increased compared to 5 years ago.
Compared to 1 year ago, PHAR has an improved debt to assets ratio.
2.2 Solvency
PHAR has an Altman-Z score of 2.56. This is not the best score and indicates that PHAR is in the grey zone with still only limited risk for bankruptcy at the moment.
With a decent Altman-Z score value of 2.56, PHAR is doing good in the industry, outperforming 74.69% of the companies in the same industry.
The Debt to FCF ratio of PHAR is 23.45, which is on the high side as it means it would take PHAR, 23.45 years of fcf income to pay off all of its debts.
With an excellent Debt to FCF ratio value of 23.45, PHAR belongs to the best of the industry, outperforming 92.16% of the companies in the same industry.
PHAR has a Debt/Equity ratio of 0.52. This is a neutral value indicating PHAR is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.52, PHAR is doing worse than 74.87% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.52 | ||
| Debt/FCF | 23.45 | ||
| Altman-Z | 2.56 |
ROIC/WACC0.29
WACC7.1%
2.3 Liquidity
A Current Ratio of 2.76 indicates that PHAR has no problem at all paying its short term obligations.
PHAR has a Current ratio of 2.76. This is in the lower half of the industry: PHAR underperforms 68.09% of its industry peers.
A Quick Ratio of 2.00 indicates that PHAR should not have too much problems paying its short term obligations.
PHAR's Quick ratio of 2.00 is on the low side compared to the rest of the industry. PHAR is outperformed by 74.33% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.76 | ||
| Quick Ratio | 2 |
3. Growth
3.1 Past
The earnings per share for PHAR have decreased strongly by -1150.00% in the last year.
The Revenue has grown by 24.13% in the past year. This is a very strong growth!
The Revenue has been growing by 10.64% on average over the past years. This is quite good.
EPS 1Y (TTM)-1150%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1057.89%
Revenue 1Y (TTM)24.13%
Revenue growth 3Y14.33%
Revenue growth 5Y10.64%
Sales Q2Q%42.28%
3.2 Future
The Earnings Per Share is expected to grow by 52.28% on average over the next years. This is a very strong growth
PHAR is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 8.40% yearly.
EPS Next Y183.09%
EPS Next 2Y10.31%
EPS Next 3Y46.06%
EPS Next 5Y52.28%
Revenue Next Year14.32%
Revenue Next 2Y10.95%
Revenue Next 3Y10.23%
Revenue Next 5Y8.4%
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for PHAR. In the last year negative earnings were reported.
Also next year PHAR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
93.23% of the companies in the same industry are more expensive than PHAR, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, PHAR is valued cheaper than 92.51% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 139.75 | ||
| EV/EBITDA | 32.24 |
4.3 Compensation for Growth
PHAR's earnings are expected to grow with 46.06% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y10.31%
EPS Next 3Y46.06%
5. Dividend
5.1 Amount
PHAR does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:PHAR (5/23/2025, 8:46:28 PM)
10.38
-0.12 (-1.14%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners15.1%
Inst Owner Change-0.19%
Ins Owners1.49%
Ins Owner ChangeN/A
Market Cap709.92M
Analysts88.57
Price Target15.73 (51.54%)
Short Float %0%
Short Ratio0.28
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-675.58%
Min EPS beat(2)-1323.95%
Max EPS beat(2)-27.22%
EPS beat(4)1
Avg EPS beat(4)-381.48%
Min EPS beat(4)-1323.95%
Max EPS beat(4)22.33%
EPS beat(8)3
Avg EPS beat(8)-226.2%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)12.4%
Min Revenue beat(2)11.43%
Max Revenue beat(2)13.36%
Revenue beat(4)2
Avg Revenue beat(4)3.97%
Min Revenue beat(4)-5.54%
Max Revenue beat(4)13.36%
Revenue beat(8)5
Avg Revenue beat(8)1.21%
Revenue beat(12)5
Avg Revenue beat(12)-2.03%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)3.15%
PT rev (3m)-0.01%
EPS NQ rev (1m)1.73%
EPS NQ rev (3m)N/A
EPS NY rev (1m)-1.73%
EPS NY rev (3m)284.07%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-2.54%
Revenue NY rev (1m)4.67%
Revenue NY rev (3m)4.67%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 2.21 | ||
| P/FCF | 139.75 | ||
| P/OCF | 116.69 | ||
| P/B | 3.32 | ||
| P/tB | 9.45 | ||
| EV/EBITDA | 32.24 |
EPS(TTM)-2.2
EYN/A
EPS(NY)-0.18
Fwd EYN/A
FCF(TTM)0.07
FCFY0.72%
OCF(TTM)0.09
OCFY0.86%
SpS4.69
BVpS3.13
TBVpS1.1
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.5% | ||
| ROE | -6.59% | ||
| ROCE | 2.59% | ||
| ROIC | 2.05% | ||
| ROICexc | 3.06% | ||
| ROICexgc | 8.39% | ||
| OM | 2.63% | ||
| PM (TTM) | N/A | ||
| GM | 88.98% | ||
| FCFM | 1.58% |
ROA(3y)-0.68%
ROA(5y)2.2%
ROE(3y)-1.17%
ROE(5y)5.07%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.48%
GM growth 5Y0.17%
F-Score5
Asset Turnover0.8
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.52 | ||
| Debt/FCF | 23.45 | ||
| Debt/EBITDA | 5.21 | ||
| Cap/Depr | 7.89% | ||
| Cap/Sales | 0.31% | ||
| Interest Coverage | 2.2 | ||
| Cash Conversion | 28.73% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.76 | ||
| Quick Ratio | 2 | ||
| Altman-Z | 2.56 |
F-Score5
WACC7.1%
ROIC/WACC0.29
Cap/Depr(3y)9.71%
Cap/Depr(5y)59.68%
Cap/Sales(3y)0.61%
Cap/Sales(5y)3.49%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1150%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1057.89%
EPS Next Y183.09%
EPS Next 2Y10.31%
EPS Next 3Y46.06%
EPS Next 5Y52.28%
Revenue 1Y (TTM)24.13%
Revenue growth 3Y14.33%
Revenue growth 5Y10.64%
Sales Q2Q%42.28%
Revenue Next Year14.32%
Revenue Next 2Y10.95%
Revenue Next 3Y10.23%
Revenue Next 5Y8.4%
EBIT growth 1Y128.99%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year21.21%
EBIT Next 3Y79.98%
EBIT Next 5Y85.48%
FCF growth 1Y284.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y750%
OCF growth 3YN/A
OCF growth 5YN/A